EASL Studio S3 E16: Liver cancer in 2022: Wrap-up & outlook

EASL Studio S3 E15: Chronic portal vein thrombosis: Anticoagulation and interventional radiology for all patients?

EASL Studio S3 E14: The future of hepatology

EASL Studio S3 E13: Next-generation metrics for science beyond journal impact factor and citations: The role of social media

EASL Studio S3 E12: Meeting the challenge of antimicrobial resistance (AMR) in cirrhosis: the invisible threat that lies within

EASL Studio S3 E11: Regenerative Hepatology: From stem cells to tissue engineering

EASL Studio S3 E10: Cholestatic pruritus: Can the itch be ditched?

EASL Studio S3 E9: JHEP Live: Antisense oligonucleotides vs. siRNAs in the treatment of chronic hepatitis B: Who will be the winner, if at all?

EASL Studio S3 E8: Transplanting patients with cancer – Is there a limit?

EASL Studio S3 Special Edition: Ending fatty liver disease as a public health threat

EASL Studio S3 E7: Bugs and the liver — The role of the gut microbiome in liver diseases

EASL Studio S3 E6: How to improve end-of-life care in liver disease?

EASL Studio S3 E5: JHEP Live: Stigma and alcohol

EASL Studio S3 E4: Special Edition: Highlights of EASL NAFLD Summit 2022

EASL Studio S3 E3: Primary biliary cholangitis: A look at the future landscape of therapy for patients

EASL Studio S3 E2: Liver transplantation for ACLF: Opportunities, challenges and pitfalls

EASL Studio S3 E1: JHEP Live: Covid vaccination and associated autoimmune hepatitis